key: cord-0764259-pz7omz97
authors: Cobb, Ronald R.; Nkolola, Joseph; Gilchuk, Pavlo; Chandrashekar, Abishek; Yu, Jingyou; House, Robert V.; Earnhart, Christopher G.; Dorsey, Nicole M.; Hopkins, Svetlana A.; Snow, Doris M.; Chen, Rita E.; VanBlargan, Laura A.; Hechenblaickner, Manuel; Hoppe, Brian; Collins, Laura; Tomic, Milan T.; Nonet, Genevieve H.; Hackett, Kyal; Slaughter, James C.; Lewis, Mark; Andersen, Hanne; Cook, Anthony; Diamond, Michael S.; Carnahan, Robert H.; Barouch, Dan H.; Crowe, James E.
title: A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
date: 2022-02-03
journal: Med (N Y)
DOI: 10.1016/j.medj.2022.01.004
sha: 4a034b87c2dca5a6fd768935d1a9611e857d21c1
doc_id: 764259
cord_uid: pz7omz97

Background Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that are engineered with mutations to extend their persistence in human serum and the neutralizing antibody titer in serum required for protection against SARS-CoV-2 infection remain poorly characterized. Methods The Fc-region of two neutralizing mAbs (COV2-2130 and COV2-2381) targeting non-overlapping epitopes on the receptor-binding domain of SARS-CoV-2 spike protein was engineered to extend their persistence in humans and reduce interactions with Fc gamma receptors. We assessed protection by individual antibodies or a combination of the two antibodies (designated ADM03820) given prophylactically by intravenous or intramuscular route in a non-human primate (NHP) model of SARS-CoV-2 infection. Findings Passive transfer of individual mAbs or ADM03820 conferred virological protection in the NHP respiratory tract in a dose-dependent manner, and ADM03820 potently neutralized SARS-CoV-2 variants of concern in vitro. We defined a protective serum neutralizing antibody titer and concentration in NHPs for passively transferred human antibodies that acted by direct viral neutralization. Conclusions In summary, we demonstrate that neutralizing antibodies with extended half-life and lacking Fc-mediated effector functions are efficient for pre-exposure prophylaxis of SARS-CoV-2 infection in NHPs. These results support clinical development of ADM03820 for COVID-19 prevention. Funding This research was supported by a contract from the JPEO-CBRND (W911QY-20-9-003), 20-05, the Joint Sciences and Technology Office and the Joint Program Executive Office (MCDC-16-01-002 JSTO, JPEO), DARPA grant (HR0011-18-2-0001), NIH grant (R01 AI157155), and the 2019 Future Insight Prize from Merck KGaA.

In the past decades, two pathogenic human coronaviruses, severe acute respiratory syndrome 83 (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV), have been reported to 84 cause severe respiratory tract disease associated with high morbidity and mortality. In December 85 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, 86 Hubei province, China 1 . SARS-CoV-2 is the causative agent of the current worldwide COVID-19 87 outbreak. The pandemic caused by COVID-19 has made the development of countermeasures an 88 urgent global priority [2] [3] [4] [5] [6] . Safe and effective vaccines and therapeutics are essential to combat this 89 global pandemic.

Initial work identified that SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) 92 protein from bats, civet cats, swine, non-human primates, or humans as an attachment and entry 93 receptor 6-8 . As with related coronaviruses, interaction with ACE2 is mediated principally through 94 the viral spike (S) protein. Hence, S on the surface of the virion is the main target for neutralizing 95 antibodies on these coronaviruses. This homotrimeric glycoprotein is anchored in the viral 96 membrane and consists of two subunits, S1, containing the N-terminal domain (NTD) and host 97 cell receptor binding domain (RBD), and S2, which contains the fusion peptide 9-10 . The S protein 98 RBD directly interacts with the peptidase domain of ACE2 [6] [7] [8] 10 . Recent studies of the S protein 99 structure have shown that the protein exists in different conformations 9, 11 . Initially, the RBD 100 switches from a closed conformation to an open conformation to allow hACE2 interaction. Upon 101 interaction with the hACE2 receptor and TMPRSS2 priming, S2 undergoes a dramatic (L234A/L235A, designated LALA) 39-41 . One conceptual advantage of this approach is that the use 128 of these antibodies lacking Fc-mediated effects allowed us to assess the level of serum neutralizing 129 activity needed in vivo to achieve efficacy in the absence of confounding variables. The resulting 130 recombinant mAbs were designated mAb COV2-2130-YTE-LALA and mAb COV2-2381-YTE-131 LALA, and a two-mAb cocktail that is a 1:1 mixture of the two was designated ADM03820. The 132 results demonstrate that ADM03820 protects against challenge with SARS-CoV-2 in the lungs 133 and nasopharynx in a dose-dependent manner and define titers of passively-transferred 134 neutralizing antibodies that are necessary for protection in NHPs. In addition, our results support 135 the use of an antibody cocktail that could be administered by either intravenous or intramuscular 136 route and that neutralizes SARS-CoV-2 variants of concern. This work provides evidence for 137 developing a cocktail of antibodies as prophylaxis against SARS-CoV-2 in high-risk individuals. infection (e.g., upper and lower respiratory tract mucosa) after 11.7 mg/kg intramuscular (IM) or 147 31.3 mg/kg intravenous (IV) administration of ADM03820 in cynomolgus monkeys ( Figure 1A) . 148 Circulating human mAbs were detected at high levels in serum on day 0 after administration 149 (median 193 g/mL after IM or 520 g/mL after IV administration) and persisted in serum for >80 150 J o u r n a l P r e -p r o o f days, exhibiting a slow and gradual decline. The median human IgG serum concentration was 9 151 g/mL on day 84 after IM or 26 g/mL after IV administration ( Figure 1B) . Notably, ADM03820 152 antibodies also were detected in respiratory tract secretions, including bronchoalveolar lavage 153 (BAL) and nasopharyngeal (NP) swabs up to 60 days after administration and at concentrations 154 ranging from 10 ng/mL (the assay limit of detection) to 270 ng/mL (Figure 1C-D) . The 155 concentration of human antibodies in these secretions in vivo prior to collection is expected to be 156 higher, given that specimen collection from the mucosa sites with saline washes resulted in administration. While antibody concentration was below the limit of detection in the sham-treated 174 group, animals in the antibody-treatment groups exhibited mAb levels proportional to the dose and 175 route of administration of the combination product ( Figure 2B ). The antibody concentration in 176 serum peaked approximately three days post-administration and remained constant throughout the 177 remaining 14 days of the study.

We observed high circulating neutralizing antibody titers by pseudovirus neutralization assays in 180 all ADM03820 treatment groups but not in the sham-treated control group. However, sham-treated 181 control animals developed low-level neutralizing titers beginning around day 6, presumably due 182 to the induction of natural host immunity ( Figure 2C ). In general, the overall neutralizing antibody 183 titers were consistent with the pharmacokinetic data for the same treatment groups.

We assessed the kinetics of viral loads up to day 14 following viral challenge in BAL and NP swab 186 samples by determining the levels of SARS-CoV-2 sub-genomic RNA (sgRNA), which 187 distinguishes replicating virus from input challenge virus, using reverse-transcriptase-polymerase 188 chain reaction (RT-PCR) 23-24,43 (Chandrashekar et al., 2020; Wolfel et al., 2020; Yu et al., 2020) .

High levels of sgRNA were observed in the sham controls ( Figure 2D -E) with a median peak of 190 5.0 (range = 3.3 to 5.4) log10 sgRNA copies/mL in BAL fluid and 6.9 (range = 4.9 to 7.3) log10 191 copies per swab of sgRNA in NP. As expected, peak viral loads occurred between days 1 to 4 after 192 challenge. All treatment groups showed nearly full protection from viral replication in the BAL 193 fluid, although individual animals displayed low-level, transient viral replication on day 1, which 194 was eliminated by day 2 (Figure 2D ). Although somewhat higher sgRNA levels were observed in 195 some animals in the NP swabs on day 1, similar to BAL fluid, most treated animals quickly 196 J o u r n a l P r e -p r o o f eliminated detectable virus by day 2 (Figure 2E) , with the exception of one animal in the group 197 receiving the lowest dose (3.9 mg/kg IM) and one animal in the group receiving 11.7 mg/kg dose. Figure 3E ) as was observed with similarly high tested doses of the 220 ADM03820 cocktail ( Figure 2E ). However, higher median viral loads were observed in the NP 221 samples for both antibody treatments at the low dose of 1.95 mg/mL. This dose is two-fold lower 222 than the lowest dose tested for the cocktail and likely represents viral breakthrough due to 223 insufficient neutralizing antibody levels. Table   244 S1-2). A threshold for virological protection in BAL fluid and NP was estimated to be equal or 245 higher than 20 g/mL for circulating human antibody concentration and equal to or higher than 246 6,000 for serum neutralizing antibody titer (NT50) (Figure 5A-D) . Antibody levels above these 247 thresholds conferred full protection in 83% to 93% of challenged NHP, which contrasted with 17% 248 to 50% fully protected animals with antibody levels below these estimated protective thresholds 249 ( Figure 5E ). Spearman's rank correlation analysis revealed a strong negative correlation between 250 serum antibody concentration and time-weighted average viral load measurements in the upper 251 airways when considering both antibody administration routes or the IM route only (Figure S1 ). 252 These results suggested that a higher antibody dose would be necessary to control viral replication that target the RBD of SARS-CoV-2 S protein 13, [16] [17] [18] [47] [48] [49] .

The studies here support the further development of a two-mAb prophylactic anti-SARS-CoV-2 290 cocktail (ADM03820) incorporating mAbs that target non-overlapping regions of the RBD 19,32 . In prior NHP studies, mAbs typically were infused via IV administration. The studies presented 342 here demonstrate the efficacy of these antibodies either administered as a combination or alone 343 when administered by the IM route This approach could provide a more broadly deployable route 344 of administration for these antibodies to patients in clinical settings. In addition, the doses that 345 were efficacious in these studies translate to very low doses in humans compared to conventional 346 antibody therapies. The data generated in these studies provides strong evidence for the continued 347 development of these antibodies for clinical use. Acknowledgements: 356 We thank E. Bondzie, N. Mercado, V. Giffin, D. Hope, and F. Nampanya for their assistance. This All authors agreed to submit the manuscript, read and approved the final draft, and take full 373 responsibility for its content, including the accuracy of the data. Table. 516  No custom computer code or algorithms to report.

 Any additional information required to reanalyze the data reported in this paper is available 518 from the lead contact upon request. On the day of administration, the stock vials were thawed at room temperature (RT) and gently 560 inverted 6 to 10 times to mix the contents. After thawing, the vials were stored at RT until use.

Based on individual animal weights and dose required, the purified antibody stock for each NHP 562 was diluted to 1 mL in 0.9% normal saline diluent (Baxter) for IM injections and 10 mL in the 563 same diluent for IV infusions. IM injections were delivered bilaterally in the upper quadriceps at 564 0.5 mL/quadriceps. IV infusions were performed at a rate of 1 to 2 mL/min over 5 to 10 min/animal 565 for a total of 10 mL infused per animal.

Animal studies 569 Cynomolgus monkeys (2.2 -5.8 kg body weight; 6 to 12 years old) were mixed male and female 570 and randomly assigned to groups. In Study 1 (n=3/group), experimental animals received the 571 ADM03820 cocktail of COV2-2130-YTE-LALA and COV2-2381-YTE-LALA at either 11.7 mg/kg IM or 31.3 mg/kg IV and were followed for 12 weeks for antibody pharmacokinetics only 573 without any SARS-CoV-2 challenge. In Study 2 (n=4/group), sham control animals received no 574 mAb while 12 experimental animals were administered the ADM03820 cocktail at varying doses 575 and administration routes three days before challenge as described in Figure 2 . Animals then were 576 challenged with 10 5 TCID50 SARS-CoV-2 USA-WA1/2020. These doses were administered as 577 0.5 mL per nare intranasally and 1 mL intratracheally on day 0. In Study 3, four sham-treated 578 controls received no mAb while 12 experimental animals (n=3/group) were administered three 579 days prior to challenge with either COV2-2130-YTE-LALA or COV2-2381-YTE-LALA 580 separately at varying doses and administration routes as described in Figure 3A . Animals were 581 then challenged with 10 5 TCID50 SARS-CoV-2 similarly as in the first study. In Study 4 582 (n=3/group), sham control animals received no mAb while experimental animals were 583 administered the ADM03820 cocktail IM at varying low doses three days before challenges 584 performed similarly to studies 2 and 3 (Figure 2,3) . In all studies, antibody doses were selected 585 based on material availability and to approximate the various dosing regimens to achieve a wide 586 concentration of circulating mAb in NHP plasma representative of low, intermediate or high levels.

Macaques in all four studies were monitored daily with an internal scoring protocol approved by 588 the IACUC. These studies were not blinded. 592 The quantification of infused/injected human SARS-CoV-2 mAbs in NHP serum at multiple time 593 points was performed as previously described 19 . Additionally, the serum neutralization activities 594 of infused or injected mAbs were also monitored at the same time points using a pseudovirus 595 neutralization assay as previously described [23] [24] . Subgenomic mRNA assay 625 The subgenomic mRNA of SARS-CoV-2 was assessed by RT-PCR as previously described [23] [24] 43 .

The standard curve is based on the SARS-CoV-2 E gene. Prior to PCR, cDNA was generated from 627 each animal using Superscript III VILO (Invitrogen) according to the manufacturer's instructions. Table S1 ). The TWA values of each treatment group were compared to those of the sham group 642 using Welch's t-test. The significance level alpha of 10% was pre-specified, and estimated P- Table S2 . Sensitivity is the proportion above the threshold in the 649 fully-protected subjects, and specificity is the proportion below the threshold in partially-or non-650 protected subjects. The fitting curves and confidence intervals to visualize the relationship 651 between TWA and antibody levels were estimated using Lowess curve smoothing method using 652 ggplot2 in R software 67 . Spearman's rank correlation analysis that assumes a monotonic (as X 653 increases, Y decrease) rather than linear relationship was used to determine the relationship Soo, Y., Rofail, D., Im, J., et al. (2020) . REGN-COV2, a neutralizing antibody cocktail, in 924 outpatients with [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] M.T., Espinoza, Y., Martinez, Z., Pham, K., Cobb, R.R., Snow, D.M., Earnhart, C.G., 927 Pals, T., Syar, E.S., Niemuth, N., et al. (2019) . Monoclonal antibody combinations prevent 928 serotype A and serotype B inhalational botulism in a Guinea pig model. Toxins 11, 208. 929 930 66. VanBlargan, L.A., Adams, L.J., Liu, Z., Chen, R.E., Gilchuk, P., Raju, S., Smith, B.K., Zhao, 931 H., Case, J.B., Winkler, E.S., et al (2021) . A potently neutralizing SARS-CoV-2 antibody 932 inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.

Immunity 54, 2399-2416.e6. C.

Ab concentration (log 10 μg/mL) C.

Ab concentration (log 10 μg/mL) A. 

A novel coronavirus outbreak of 659 global health concern

A familial cluster of pneumonia associated with the 2019 novel 663 coronavirus indicating person-to-person transmission: a study of a family cluster

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus 668 pneumonia in Wuhan, China: a descriptive study

Early transmission dynamics in Wuhan, China, of Novel Coronavirus-672 infected pneumonia

A new coronavirus associated with human respiratory disease in China

Cryo-EM analysis of the post-fusion 702 structure of the SARS-CoV spike glycoprotein

Potent neutralizing antibodies against SARS-CoV-2 identified by high-706 throughput single-cell sequencing of convalescent patients' B cells

Cross-neutralization of SARS-CoV-2 by a 713 human monoclonal SARS-CoV antibody

Isolation of potent SARS-CoV-2 neutralizing antibodies and 717 protection from disease in a small animal model

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. 721

DNA vaccine protection against 749 SARS-CoV-2 in rhesus macaques

Coronavirus (COVID-19) Update: FDA authorizes monoclonal antibodies for 752 treatment of COVID-19

Coronavirus (COVID-19) Update: FDA authorizes additional monoclonal 757 antibody for treatment of COVID-19

FDA authorizes REGEN-COV monoclonal antibody therapy for post-762 exposure prophylaxis (prevention) for COVID-19

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint 767 in preventing COVID-19 (press release

CoV-2 variant strains (2021b)

Complete mapping of mutations to 799 the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

Phase I evaluation of humanized OKT3: toxicity and 804 immunomodulatory effects of hOKT3gamma4

Potential mechanisms for thrombocytopenia 808 development with trastuzumab emtansine (T-DM1)

The role of C5a in acute lung 811 injury induced by highly pathogenic viral infections

Goat Anti-Mouse IgG Antibody, HRP conjugate Sigma Cat